Luye Pharma
Luye Pharma Group is a leading specialty pharmaceutical company based on research and development.
Launch date
Employees
Market cap
AUD2.1b
Enterprise valuation
AUD2.5b (Public information from Sep 2024)
Share price
HKD2.98 2186.HK
Wauchula Florida (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 5.5b | 5.2b | 6.0b | 6.1b | 6.8b | 7.8b | 8.9b |
| % growth | (13 %) | (6 %) | 15 % | 3 % | 11 % | 14 % | 14 % |
| EBITDA | 1.9b | 969m | 1.9b | 1.9b | 1.8b | 2.1b | 2.4b |
| % EBITDA margin | 35 % | 19 % | 32 % | 31 % | 27 % | 27 % | 27 % |
| Profit | 707m | (134m) | 605m | 533m | 736m | 1.0b | 1.3b |
| % profit margin | 13 % | (3 %) | 10 % | 9 % | 11 % | 13 % | 14 % |
| EV / revenue | 2.9x | 3.3x | 2.6x | 2.6x | 1.9x | 1.6x | 1.4x |
| EV / EBITDA | 8.2x | 17.5x | 8.3x | 8.3x | 7.1x | 6.2x | 5.2x |
| R&D budget | 790m | 683m | 857m | 586m | - | - | - |
| R&D % of revenue | 14 % | 13 % | 14 % | 10 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
* | CNY1.6b | Post IPO Equity | |
| Total Funding | - | ||
Related Content
Recent News about Luye Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Luye Pharma
Edit
ACQUISITION by Luye Pharma Dec 2019